Tacrolimus (Protopic) Ointment
Tacrolimus was specifically developed for the treatment of eczema. It was first approved in Japan in 1999 for eczema. More than 19000 patients (including 7600 children) took part on the Tacrolimus ointment development programme. More than 5.4 million prescriptions have been issued worldwide.
No evidence of increased risk of malignancy in adults or children compared with the general population.1
This is an ointment that is used for the treatment of moderate to severe eczema in patients who have not responded to conventional treatment. Recently its use as a twice weekly application has been suggested to keep eczema at bay.
Reference
- Rustin MHA. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. BJD 2007; 157: 861-873
|
